Modern Action logo
IssuesBillsBriefingNewsletterAbout
Donate
Donate
Modern Action

Navigation

Menu

01HomeFront page→02IssuesActive issue pages→03BillsLegislation index→04BriefingDaily context→05NewsletterWeekly Watchlist→06AboutMission and team→07DonateSupport the work→

Account

Sign In→Get Started→
Modern Action

Find the bills behind the news, understand what Congress can do, and contact your representatives with a specific message.

Platform

  • Contact Congress
  • Write to Congress
  • Browse Bills
  • Bill Explainers
  • Track Bills

Resources

  • Find My Representatives
  • Contact My Representatives
  • How to Contact Representatives
  • Does Contacting Congress Work?
  • Newsletter

Support

  • About
  • Contact Us
  • Press
  • Accessibility

Legal

  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Accessibility

Stay informed about legislation

Get weekly updates on important bills and how to take action.

© 2026 Modern Action. All rights reserved.

Made with ❤️ for democracy
All systems operational

Contact Congress about S. 3345: PBM Price Transparency and Accountability Act

The bill would ban spread pricing in Medicaid and make PBM payment rules more transparent in Medicaid and Medicare Part D. It would also set new standards for pharmacy contracts and access in Medicare drug plans. PBMs, plans, states, and pharmacies would all face new reporting, audit, and enforcement rules.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

PBM Price Transparency and Accountability Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 3345: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects independent pharmacies, rural pharmacies, PBMs, Medicare drug plans, and state Medicaid programs. Medicare Part D patients could also feel the effects if plan networks change or if local pharmacies get stronger protections. Federal regulators would take on a bigger role because they would set standards, collect data, investigate complaints, and enforce the new rules.

Why this matters: This bill matters because it could change who keeps money inside the prescription drug system and how visible those payments are. Today, states and plans may not fully see how PBMs, pharmacies, rebates, and fees interact. The bill tries to make those flows clearer, tie some payments more closely to real drug costs, and protect access to local pharmacies. It could shift money away from hidden margins and toward more direct payment rules, but the final effect on costs and patient access would still depend on how plans, PBMs, states, and regulators act.

Key provisions in S. 3345

  • Pharmacies would have to answer monthly national surveys about what they pay to buy drugs. That applies to retail pharmacies and some non-retail pharmacies, and refusing could bring civil fines of up to $100,000 for each violation.
  • HHS would have to publish summary results from those drug cost surveys. The public release must include response rates, sampling methods, and overall data on pharmacy price concessions.
  • States could not use non-retail pharmacy price data to set payment rules for retail community pharmacies. Retail payment methods would have to rely on retail pharmacy data instead.
  • Medicaid contracts with managed care plans and PBMs would have to use a transparent pass-through model. Drug payment could cover only ingredient cost plus a professional dispensing fee, and spread pricing would not count for federal matching funds.
  • PBMs and health plans in Medicaid could charge only fair-market-value administrative fees. They would also have to fully disclose drug costs, fees, discounts, and other payments to states and, if asked, to HHS.

How Modern Action helps you take action on S. 3345

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 3345

What is S. 3345?
The bill would ban spread pricing in Medicaid and make PBM payment rules more transparent in Medicaid and Medicare Part D. It would also set new standards for pharmacy contracts and access in Medicare drug plans. PBMs, plans, states, and pharmacies would all face new reporting, audit, and enforcement rules.
How do I support or oppose S. 3345?
Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
Who should I contact about S. 3345?
Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
Can Modern Action explain S. 3345 before I act?
Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.

Keep acting on Modern Action

More ways to act on this issue

Compare the broader issue and related bills without leaving Modern Action.

Related issues

  • Contact your reps on PBM, drug-cost, and price transparency reformsWhether Congress should reduce underlying health costs through pharmacy benefit manager reporting, rebate pass-through, provider price posting, health plan data access, and clearer medical bills.
  • Contact your reps on Medicaid and Medicare Drug Payment DataPublic programs would collect pharmacy acquisition costs, publish benchmarks, require Medicaid pass-through pricing, adjust lab-test payment data, and study or disclose public-program drug payments.
  • Contact your reps on PBM Rebates, Spread Pricing, and Pharmacy PaymentsPBMs would disclose or pass through rebates, stop hidden spread pricing, limit clawbacks, delink compensation from drug prices, report pharmacy steering, and face audits or penalties.
  • Contact your reps on Medicaid Pharmacy, PBM, And Value-Based Drug PaymentsRules for Medicaid drug payment formulas, pharmacy acquisition-cost surveys, PBM spread pricing, rebate pass-through, 340B reporting, and value-based drug purchasing arrangements.
  • Contact your reps on Medicare Drug Payment and Pharmacy AccessMedicare Part B or Part D drug payment rules tied to outpatient care, PBM compensation in Medicare, rebates, pharmacy network access, formulary oversight, pharmacy performance fees, and drug cost-sharing calculations.

Related bills

  • Take action on H.R. 1768: Lower Costs for Everyday Americans Act
  • Take action on S. 891: Bipartisan Health Care Act
  • Take action on H.R. 4317: PBM Reform Act of 2025
  • Take action on H.R. 6703: Lower Health Care Premiums for All Americans Act
  • Take action on H.R. 6501: Bipartisan Health Insurance Affordability Act
  • Take action on S. 3389: Lowering Health Care Costs for Americans Act
  • Take action on H.R. 5269: RESULTS Act
  • Take action on H.R. 1613: Drug Price Transparency in Medicaid Act of 2023